All In MedTech

Device Trial Radar · NCT05940597

Pulsed Field Ablation vs Cryoablation In Paroxysmal Atrial Fibrillation

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 354 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

354

Actual

Start

Sep 25, 2023

Primary completion

Mar 23, 2026

Study completion Mar 23, 2026

Sponsor

Lead sponsor
University Hospital, GrenobleAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Boston Scientific Corporation
First posted
Jul 11, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cryoballoon pulmonary vein isolation (PVI) has emerged as an alternative to radiofrequency in the treatment of drug-resistant atrial fibrillation (AF). (1) Cryoablation offers potential advantages over radiofrequency, including shorter procedure times, decreased fluoroscopy time, shorter hospital length of stay, and different rates and types of complications. (2) The efficacy over a mean follow-up of one year with cryoablation for AF is comparable to that of radiofrequency ablation in a prospective randomized trial, with a lower major complication rate (3, 4). In recent years, AF cryoablation has established itself as a real alternative to RF ablation, to the point that this ablative source is chosen in one out of five European patients undergoing PV isolation. 70-80% of patients maintain sinus rhythm after a first procedure, showing an efficacy rate equivalent to ablation by RF. It is also comparable to RF when it comes to safety. Phrenic nerve palsy remains the major concern of cryoablation, accounting for 40% of periprocedural complications. A reduction in total procedure time and less dependence on the operator's experience make cryoablation an attractive choice for centres starting an AF ablation program. In conclusion, we do not yet have definitive data to affirm the superiority of one energy source over the other. Generally the choice depends on the availability of the centre and on the experience of the operator. Pulse field ablation (PFA): Vivek Y. Reddy demonstrates that in patients with paroxysmal atrial fibrillation, PFA rapidly and efficiently isolates PVs with a degree of tissue selectivity and a safety profile(1).PFA can achieve a high degree of durable PV isolation with a comparable efficiency than another techniques (RF or CRYO) at one year follow-up (2) Cryoablation has been a recognised technique for the ablation of atrial fibrillation for many years, with many studies comparing the technique to radiofrequency ablation with equal results. Studies are underway to compare radiofrequency AF ablation versus PFA (BEAT-AF study). A randomized study to compare two methods of cryoablation versus PFA will be necessary to validate the non-inferiority of the technique.

Conditions

  • Atrial Fibrillation Paroxysmal

Interventions

  • Pulse field ablationDevice

    ablation of paroxysmal atrial fibrillation by Pulse field ablation

  • Cryoballoon pulmonary vein isolationDevice

    ablation of paroxysmal atrial fibrillation by Cryoballoon pulmonary vein isolation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. proportion of subjects experiencing one-year single-procedure clinical successTime frame: 12 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • CHU Caen Normandie

    Caen, France

  • Chu Grenoble Alpes

    Grenoble, France

  • CHU Montpellier

    Montpellier, France

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.